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Aims: To compare the metrics and surgical outcome when using Inﬁ  niti AquaLase and NeoSoniX cataract removal 
modalities.
Methods: This prospective clinical study involved 50 patients with bilateral cataracts and lens removal using 
AquaLase in the right eye and NeoSoniX in the left eye. Best corrected visual acuity (BCVA), endothelial cell density 
and pachymetry were evaluted pre- and postoperatively. Statistical analysis was performed using the Wilcoxon Signed-
Rank Test. 
Results: Preoperative mean pachymetry was 569 ± 31 μ in the right eye (RE) and 560 ± 37 μ in the left eye (LE), 
mean endothelial cell density 2744 ± 418 cells/mm2 (RE) and 2730 ± 472 cells/mm2 (LE). One week after operation 
pachymetry was 576 ± 52 μ (RE) and 583 ± 72 μ (LE) and endothelial cell density 2388 ± 586 cells/mm2 (RE) and 
2463 ± 615 cells/mm2 (LE). One month after surgery pachymetry was 556 ± 43 μ (RE) and 559 ± 44 μ (LE) and 
endothelial cell density 2368 ± 52 cells/mm2 (RE) and 2495 ± 548 cells/mm2 (LE). BCVA improved in all eyes and 
was 0.8 or better on the ﬁ  rst postoperative day. 
Conclusions: Both the NeosoniX and AquaLase minimize intraoperative damage to ocular structures.
INTRODUCTION
Phacoemulsiﬁ  cation has become the current preferred 
procedure for cataract removal1–4. Continual improve-
ments in new technologies and techniques allow cataract 
surgery to be performed even more safely and eﬃ   ciently5–7. 
The quest for lens extraction involving reduced intraocular 
energy has been fulﬁ  lled with power modulations and sup-
plemental energy sources, with improved outcomes8–10.
Conventional ultrasonic (US) phacoemulsiﬁ  cation is 
created in a handpiece when power is applied to piezo-
electric crystals which convert the electrical energy into 
mechanical vibrations of the phaco needle. The phaco 
needle tip is used to emulsify the lens material at ultra-
sonic frequencies generally between 25 KHz and 62 KHz, 
which creates both thermal and cavitational energy with 
potential damage to the cornea. NeoSoniX handpiece de-
livers oscillatory sonic and axial ultrasonic energy sepa-
rately or in combination. The phaco tip has a variable 
rotational oscillation up to 2 degrees at an approximate 
frequency of 100 Hz. This lower frequency produces no 
signiﬁ  cant thermal energy and thus minimizes the risk for 
thermal injury. Previous studies11 suggest that US coupled 
with oscillatory motion is more eﬃ   cient than just applying 
axial energy alone.
The AquaLase liquefaction device is one of the most 
recent innovations in phacoemulsiﬁ  cation. Warmed pulses 
(57 °C) of balanced salt solution (BSS) are used to strain 
and dissolve the lens for aspiration. Within the AquaLase 
handpiece, 4 μL ﬂ  uid pulses are generated as current pass-
es between electrodes. These pulses then travel from the 
handpiece into the tip of the instrument and eventually 
into the eye. The ﬂ  uid pulses pass through a channel in 
the outer sleeve of the tip and exit through a single small 
opening located in the lumen of the polymer application 
tip near its distal end. Aspiration of the liqueﬁ  ed lens 
material occurs through the central lumen of the tip. The 
BSS pulses are delivered at a maximum rate of 50 Hz, and 
the magnitude of the pulses can be linearly controlled by 
foot-pedal depression.
The purpose of this study was to compare the metrics 
and surgical outcome using AquaLase and NeoSoniX 
cataract removal modalities.
 MATERIALS AND METHODS
This prospective clinical study included 50 patients 
with bilateral lens opaciﬁ  cation scheduled for cataract 
surgery at the Department of Ophthalmology, University 
Hospital, Hradec Králové. Patients were selected from 
the waiting list. To be eligible for the study, both eyes had 
to have cataract preferably with similar grades of density. 
Patients with ocular surface disease, endothelial or stro-
mal corneal dystrophies as well as corneal scars, macular 
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erative visual recovery were excluded. The purpose, proce-
dures, and responsibilities were explained to all potential 
participant, and informed consent was obtained. 
Before surgery, a complete eye examination was per-
formed. Best corrected distance visual acuity was meas-
ured using Snellen optotypes, endothelial cell density 
and pachymetry using specular microscope CONAN 
NONCON ROBO. Cataracts were graded clinically on 
the basis of their hardness according to the Buratto clas-
sification2 (grade 1–5 scale). Patients with very hard 
nucleus (grade 5 – brown or black hard-rock cataracts) 
were not included in this study. Surgery was performed 
by two surgeons (NJ, PR), one surgeon per patient (both 
eyes). Phacoemulsiﬁ  cation was performed under topical 
anesthesia via 3.0 mm limbal incision using AquaLase in 
the right eye and NeoSoniX in the left eye. The standard 
AquaLase soft polymer needle (ﬂ  ared at the tip) with a 
1.1 inner diameter and a 1.32 mm outer diameter was 
used in the case of AquaLase procedures and a 30-degree 
round 1.1 mm ﬂ  ared ABS tip in the cases of NeoSoniX 
use. The phaco settings were modiﬁ  ed for each cataract 
grade on both lens removal modalities (Table 1 and 2). 
AcrySof Single Piece IOLs (Alcon) were implanted in the 
bag through a Monarch II injector system. All patients 
received topical tobramycin 3.0 mg /mL and dexametha-
sone 1.0 mg/mL (Tobradex®) ﬁ  ve times daily for 2 weeks 
postoperatively, followed by dexamethasone 1,0 mg/mL 
(Dexamethason®) three times daily for 2 weeks. 
Best corrected Snellen visual acuity at a distance was 
measured on the ﬁ  rst postoperative day, 1 week and 1 
month after surgery. Endothelial cell density and pachym-
etry were evaluated 1 week and 1 month after surgery. The 
mean values of pachymetry and endotellial cell density 
were calculated, as well as standard deviation (SD) of the 
means in each group. Statistical analysis of the postopera-
tive changes of pachymetry (diﬀ  erence between the post-
operative and preoperative values) and ECC (diﬀ  erence 
between the preoperative and postoperative values) was 
performed using the Wilcoxon Signed-Rank Test, which 
compares, pair by pair, the rank values of the selected 
variables, and displays the count of positive and negative 
diﬀ  erences.
RESULTS
Phacoemulsiﬁ  cations Metrics
The mean AquaLase time was 1.04 ± 1.16 seconds. 
Number of pulses varied from 0 (soft lens where only 
irigation/aspiration using high vacuum was employed) to 
5280 (hard cataract grade 4). The median value was 975 
pulses, the mean value was 1353 ± 1407 pulses. Fixed ﬂ  ow 
and vacuum were used in all AquaLase cases, the dynamic 
rise was chosen 2 or 3 (Table 1). The peak vaccum varied 
from 141 mmHg to 729 mmHg, median 545, mean 520 
± 95 mm Hg.
In the NeoSoniX phacoemulsifications the mean 
phaco power was 6.9 ± 4.7 % and the mean eﬀ  ective phaco 
time was 7.14 ± 5.8 seconds. Fixed ﬂ  ow and vacuum were 
used in all eyes and the dynamic rise was 3 or 4 (table 2). 
The peak vacuum varied from 380 to 696 mmHg, median 
549.5, mean 545.7 ± 62.1 mmHg. 
Surgical Outcomes
Preoperative mean pachymetry was 569 ± 31 μ in the 
right eye (RE) and 560 ± 37 μ in the left eye (LE), mean 
endothelial cell density 2744 ± 418 cells/mm2 (RE) and 
2730 ± 472 cells/mm2 (LE). One week after operation 
pachymetry was 576 ± 52 μ (RE) and 583 ± 72 μ (LE) 
and endothelial cell density 2388 ± 586 cells/mm2 (RE) 
and 2463 ± 615 cells/mm2 (LE). One month after surgery 
pachymetry was 556 ± 43 μ (RE) and 559 ± 44 μ (LE) 
and endothelial cell density 2368 ± 52 cells/mm2 (RE) 
and 2495 ± 548 cells/mm2 (LE) (Figures 1 and 2). The 
diﬀ  erences in postoperative changes in pachymetry and 
ECC between AquaLase and NeosoniX groups were not 
statistically signiﬁ  cant, except for pachymetry at 1 month 
follow-up where the results were better in the AquaLase 
group. 
Fig. 1.  Mean pachymetry values and standard devia-
tions in AquaLase and NeoSoniX groups preop-
eratively, 1 week and 1 month after operation. 
At one month follow-up there was a statistically 
signiﬁ  cant diﬀ  erence between both groups in the 
postoperative changes (diﬀ  erence between post-
operative and preoperative values) *.
Fig. 2.  Mean endothelial cell density values and standard 
deviations in AquaLase and NeoSoniX groups 
preoperativelly, 1 week and 1 month after opera-
tion313 AquaLase versus NeoSoniX – A comparison study
Table 1. AquaLase settings for each cataract grade
Grade Linear Magnitude Burst Fluidics – ﬁ  xed ﬂ  ow & vacuum Dynamic Rise
1 60 % @ 40pps 50 % 96 cm, 36 cc/min, 500mmHg 2
2 80 % @ 50pps 50 % 100 cm, 40 cc/min, 550mmHg 2
3 100 % @ 50pps 50 % 105 cm, 40 cc/min, 600mmHg 3
4 100 % @ 50pps 70 % 105 cm, 40 cc/min, 650+mmHg 3
pps = pulses per second 
Table 2. NeoSoniX settings for each cataract grade.
Grade Fixed Burst NeoSoniX
Amplitude
Fluidics – ﬁ  xed ﬂ  ow & vacuum Dynamic Rise
1 25 %, 50 ms 50 %   60 cm, 36 cc/min, 400 mm Hg 3
2 30 %, 20 ms 60 %  90 cm, 40 cc/min, 550 mm Hg 3
3 50 %, 20 ms 70 %  90 cm, 40 cc/min, 600 mm Hg 3
4 70 %, 80 ms 80 % 100 cm, 40 cc/min, 650+ mm Hg 4
Table 3. Status of the cornea on the ﬁ  rst postoperative day in AquaLase and NeoSonix groups.
Status of cornea
AqL NS/U
eyes % eyes %
crystal clear, no trace 
of striae or edema 48 96 47 94
mild epithelial edema 
and striae 243 6
AqL = AquaLase
NS/U = NeoSoniX
BCVA improved in all eyes and was 20/25 or better 
(1.0 to 0.8) immediately after operation. The cornea 
was crystal clear (no trace of striae or edema) in 48 eyes 
(96 %) in the AquaLase group and in 47 eyes (94 %) 
in the NeoSoniX group on the ﬁ  rst postoperative day 
(Table 3). 
DISCUSSION
The art and science of cataract removal through 
Kelman ultrasonic phacoemulsiﬁ  cation12,13 is constantly 
evolving – continual improvements in phaco technique 
and technology have made the procedure more safe and 
eﬃ   cient than was possible in the past. Surgeons need to 
encorporate new developments to achieve the greatest 
possible patient beneﬁ  t.
The Inﬁ  niti Vision System (Alcon Laboratories, Fort 
Woth, Texas) is the newest addition to the Alcon line 
of phacoemulsiﬁ  cation instruments. It oﬀ  ers various op-
tions for lens removal, including traditional ultrasound, 
NeoSoniX and AquaLase. NeoSoniX was originally intro-
duced as an upgrade of the Alcon Legacy and in addition 
to conventional US phacoemulsiﬁ  cation, the NeoSoniX 
option adds oscillations up to 2 degrees at an approximate 
frequency 100 Hz. The addition of oscillattory movement 
improves surgeon control and occlusion management, en-
hances cutting performance, allowing lower energy pro-
duction with resultant lower risk of intraoperative damage 
and better surgical outcomes11, 14.
Rather than using mechanical US energy from a vibrat-
ing phaco needle, the AquaLase handpiece uses warmed 
pulses of balanced salt solution (BSS) to emulsify the lens 
material for aspiration15, 16. AquaLase oﬀ  ers the advantage 
of potentially reducing the risk of damage to intraocular 
tissues because the ﬂ  uid pulses are quickly dampened in 
the eye’s ﬂ  uid environment. The attenuation eﬀ  ect very 
rapidly spreads elsewhere in the eye – there is no radiating 
ultrasonic pressure wave. The other fundamental diﬀ  er-
ence between AquaLase and conventional US phacoe-
musiﬁ  cation is that there is no possibility of incision 
burn from AquaLase. In conventional US lens removal, 
thermal tissue damage at the incision site is a potential 
complication with signiﬁ  cant sequellae17, 18. The solution 
used by AquaLase is warmed to 57°C, and experimental 
measurement of internal wound temparature has shown 
that no incision heat is generated even at full power16. The 
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decreased risk of rupture of the posterior capsule. In this 
limited series we have not seen any of this intraoperative 
complication.
We have been using the Inﬁ  niti Vision System since 
July 2004. We now routinely use only NeoSoniX or 
AquaLase in 100 % of our cases. Based on our own expe-
rience, there is a short learning curve for the experienced 
US phacoemulsiﬁ  cation surgeon in adopting AquaLase. 
We perform routinely quick–chop technique when using 
NeoSoniX. We have found that AquaLase liquefaction 
is performed more eﬃ   ciently with prechopping of the 
nucleus. Once the pieces are created – whether by groov-
ing, chopping or prechopping, we found it beneﬁ  cial to 
remove them with as little motion of the tip as possible. 
This was achieved by using ﬁ  xed ﬂ  ow and ﬁ  xed vacuum 
to optimize occlusion. 
Both AquaLase and NeoSoniX proved to be safe and 
eﬃ   cient for cataract removal in our survey. There was 
minimal change in corneal thickness after surgery with 
the results slightly better in the AquLase group. There 
was no signiﬁ  cant loss of the endothelial cells in either 
groups.
The only limitation of AquaLase that we have found is 
that it is not as eﬀ  ective as NeoSoniX in the case of harder 
cataracts (grade 4 and 5). With these harder lenses, the 
NeoSoniX use of axial US energy coupled with oscilla-
tions of the tip appears more eﬀ  ective. AquaLase easily 
extracts all cataracts of grade 1 and 2. With prechop-
ping of the nucleus, AquaLase is also able to eﬃ   ciently 
remove dense cataracts of grade 3 and many of grade 4. 
For those cases, where lens density was too hard for ef-
ﬁ  cient AquaLase use, we were able to easily transition to 
the NeoSoniX handpiece with minimal eﬀ  ort.
One of the reasons we suspect that AquaLase is so 
successful is through the impressive ﬂ  uidics of the Inﬁ  niti 
Vison System. We found we were able to safely use high 
vacuums (400 to 650+ mm Hg) and high flow rates 
(40 mL/min) with full occlusion of the aspiration port. 
The AquaLase is one of the most promising new tech-
nologies available today and the techniques for its use are 
still evolving. Because it is exceedingly diﬃ   cult to rupture 
the posterior capsule while using AquaLase, this modal-
ity is excellent for polishing the capsule and removing 
lens epitelial cells. AquaLase is especially well suited to 
refractive lens procedures and pediatric cataracts. With 
prechopping of the nucleus we now use AquaLase in 
60–70 % of our cataract cases in which we are removing 
even hard and dense nuclei. 
CONCLUSUION
In conclusion, the results of our bilateral 50 patient 
study demonstrated that both Infiniti AquaLase and 
NeoSoniX modalitis using the Infiniti Vision System 
provided similar high-quality post-operative results There 
was a statistical signiﬁ  cant diﬀ  erence in the postoperative 
changes for pachymetry with better results in AquaLase 
group using the Wilcoxon Signed-Rank Test one month 
later. The inherent design of AquaLase essentially elimi-
nates the possibility of wound site thermal injury. The 
softer tip is more capsule friendly. Since our study ap-
pears to show that AquaLase provides similar and perhaps 
slightly improved outcomes, it is a method we try to use 
on all cataracts of grades 1–3. We believe this new techo-
logy minimizes intraoperative damage to ocular structures 
and maximizes the level and rapidity of visual rehabilita-
tion. 
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